Close Menu

People in the News

May 27, 2020

Flagship Biosciences: Aymii Couzelis

Flagship Biosciences has promoted Aymii Couzelis to CIO. As such, she will oversee scaling of technology across software development, the customer help desk, network engineering, project management, quality assurance, laboratory operations, and data security, the company said. Couzelis has been with Flagship Biosciences for about a year, previously as technology manager. She formerly was CIO of corporate wellness firm MediFit Corporate Services.

May 26, 2020

Progenity: Damon Silvestry

Molecular testing firm Progenity has appointed Damon Silvestry its chief operating officer. Silvestry has more than 15 years of experience in strategic lab and business operations, including stints at Natera, Miraca Life Sciences, and Dell. He was most recently senior vice president, operations and people office at Natera.

May 26, 2020

Freenome: Bill Quirk, Gary Reedy

Freenome has hired Bill Quirk as its chief financial officer. Prior to joining Freenome, Quirk served as a managing director in the equity research division of investment bank Piper Sandler. He received a BA in business administration from Saint Norbert College, an MBA from the University of Minnesota’s Carlson School of Management, and holds the CFA designation.

The company also announced that Gary Reedy has joined its board of directors as an observer. Reedy became CEO of the American Cancer Society in April 2015, having worked with the organization for more than 20 years. He boasts a 37-year career as a healthcare business and advocacy leader, most recently as worldwide VP of government affairs and policy at Johnson & Johnson. He also held senior leadership positions with SmithKline Beecham, Centocor, and Johnson & Johnson. Reedy is a graduate of Emory & Henry College and holds an honorary Doctor of Humane Letters degree from Arcadia University.

May 20, 2020

Meridian Bioscience: Tony Serafini-Lamanna

Meridian Bioscience promoted Tony Serafini-Lamanna to executive VP of diagnostics, passing responsibility of the diagnostics division from CEO Jack Kenny and making Serafini-Lamanna an officer of the company. He was previously the global VP and general manager of diagnostics, a position he held since April 2018. The promotion became effective May 18. 

Before joining Meridian, Serafini-Lamanna worked at Siemens Healthcare Diagnostics as general manager for diagnostics Canada and VP of marketing for North America. 

May 19, 2020

Sema4: Martin Chavez

Sema4 has appointed Martin Chavez to its board of directors. Chavez served in several senior roles at the investment bank Goldman Sachs, including chief information officer, CFO, and global cohead of the firm's securities division. He was also a member of the firm's management committee.

Chavez cofounded Kiodex and Quorum Software Systems, which provide software for the finance and oil and gas industries, respectively.In addition to Sema4, Chavez serves on the boards of Paige, an AI biomedical tech startup, and Recursion, a software-based drug discovery company. This month he was named president of the Harvard Board of Overseers and serves on the Stanford Medicine board of fellows and the Institute for Advanced Study's board of trustees.

Chavez holds a master's degree in computer science from Harvard and a doctorate in Medical Information Sciences from Stanford University.

May 15, 2020

Centogene: Sun Kim, Oved Amitay

Sun Kim will become interim chief business officer of Centogene, effective June 1. He will replace Oved Amitay, who will leave the company on May 31, until a permanent chief business officer has been appointed. Kim is currently Centogene's chief strategy and investor relations officer. Prior to that, he was head of corporate strategy at Shire, and before that, he held multiple roles in the Alcon division of Novartis. Kim holds PhD and MS degrees in chemical engineering from Stanford University.

May 13, 2020

Thermo Fisher Scientific: Garret Hampton

Garret Hampton has been appointed as president of the clinical next-generation sequencing and oncology business at Thermo Fisher Scientific. He joins the firm from Illumina, where he was senior VP of clinical genomics. Before that, he was VP and global head of oncology biomarker development and companion diagnostics at Genentech. Hampton holds a PhD in cancer genetics from the University of London and an undergraduate degree in natural sciences from Trinity College Dublin.

May 12, 2020

Genentech: Aviv Regev

Aviv Regev will join Genentech as head of research and early development, effective August 1. She will replace Michael Varney, who will retire from his post at the end of July, and will also join Genentech's enlarged corporate executive committee. Regev is currently faculty chair, core institute member, and a member of the executive leadership team at the Broad Institute, as well as a professor of biology at the Massachusetts Institute of Technology and a Howard Hughes Medical Institute investigator. Prior to that, she was a Bauer fellow at the Center for Genomics Research at Harvard University. Regev holds a PhD in computational biology and a master of science degree from Tel Aviv University.

May 12, 2020

Seer: Omead Ostadan

Omead Ostadan will join Redwood City, California-based proteomics firm Seer as president and chief operating officer, effective June 29. He will also join the company's board of directors. Ostadan is currently chief product and marketing officer and a member of the executive management team of Illumina. He joined Illumina in 2007 as VP of marketing after the firm acquired Solexa, where he served in the same position. Prior to that, he held various marketing roles at Applied Biosystems. Ostadan holds a BS in biochemistry from the University of California, Davis, and an MBA from the Wharton School at the University of Pennsylvania.

May 12, 2020

Alveo Technologies: Bharat Tewarie

Alveo Technologies has appointed Bharat Tewarie to its board of directors. Tewarie recently founded Boston BioPharma Consultants and was formerly executive vice president and chief marketing officer at biopharma firm UCB. He currently is on the board of Ahara Biosciences and Duluth Medical Technologies. Alameda, California-based Alveo is developing an at-home diagnostic platform called be.well that leverages nucleic acid amplification for the molecular detection of infectious diseases.

May 12, 2020

Nucleix: Chris Hibberd, Todd Myers, Eyal Miller, Thomas Buchholz

Nucleix has appointed several individuals in executive and other leadership roles. The firm has appointed Chris Hibbered as CEO, while Opher Shapira will become a strategic business advisor to the firm. Hibberd previously served as CEO and cofounder of Astute Medical before it was acquired by bioMérieux. Prior to Astute Medical, Hibberd was senior VP of corporate development at Biosite Discovery.

The company has also appointed Todd Myers as CFO, and Eyal Miller as general manager for Europe, Middle East, and Africa, as well as managing the firm's operations in Rehovot, Israel.

Myers previously served as CFO of Astute Medical before it was acquired by bioMérieux. Before Astute, Myers was CFO at SGX Pharmaceuticals. He was also director of finance at CombiChem.

Before Nucleix, Miller served as VP and head of the healthcare division at Stratasys. Prior to Stratasys, Miller was CEO at Common Sense. Before working at Common Sense, Miller was a senior director and general manager of Europe at Touchstone International Medical Science Co.

Thomas Buchholz, who is currently the medical director of Scripps MD Anderson Cancer Center, will also join the firm's board. He served a six-year term as the co-chair of the Breast Cancer Steering COmmittee of the National Clinical Trials Network at the National Cancer Institute.

May 11, 2020

Roche: Fritz Gerber

Roche announced that former Group CEO and Chairman of the Board Fritz Gerber died at 92. Gerber served as group CEO from 1978 to 1998 and decentralized the company's structures. Under his leadership, Roche acquired a majority stake in Genentech, took over Boehringer Mannheim, and acquired PCR technology. After retiring as chairman in 2001, he remained an honorary chairman throughout the rest of his life. 

Gerber was also on the board of IBM and created the Fritz Gerber Foundation for Gifted Young People.

May 08, 2020

Fluidigm: Sam Colella, Carlos Paya, Pat Jones, Laura Clague

Sam Colella, chairman of Fluidigm's board of directors, and Pat Jones, current audit committe chairman, will retire from the company's board, Fluidigm President and CEO Chris Linthwaite said during the company's earnings conference call this week. 

Carlos Paya, a trained immunologist, infectious disease expert, and physician, has been elected as the new chairman. In addition, Laura Clague will become the new audit committee chairwoman.

May 07, 2020

ArcherDx: Jason Ryan

ArcherDx has appointed Jason Ryan to the firm's board of directors and as the chair of its audit committee. Ryan currently serves as chief operating and financial officer at Magenta Therapeutics. He previously served as CFO at Foundation Medicine before it was sold to Roche Diagnostics in 2018. 

May 07, 2020

M2Gen: Chris Tunnell

M2Gen has hired Chris Tunnell as VP of global sales. Tunnell joins the oncology-focused informatics company after serving as chief sales and revenue officer of Inspirata. He previously was interim CEO, chief revenue officer, and cofounder of PS Data Insights, among other sales and revenue management jobs he has held in the biotech and informatics fields.  

May 06, 2020

Personalis: Stephen Moore

Personalis has appointed Stephen Moore as general counsel. Prior to this new role, Moore spent a decade at Pacific Biosciences, where he also served as general counsel. Before that, he was general counsel at Navigenics, a consumer genomics company that was later acquired by Life Technologies (now part of Thermo Fisher Scientific). Prior to Navigenics, he worked for over eight years at DNA microarray company Affymetrix (also acquired by Thermo Fisher). Moore holds a BA degree in political science from San Jose State University, and a law degree from the University of California, Davis.

May 06, 2020

Centogene: Angelos Baxevanis

Angelos Baxevanis has joined Centogene as senior vice president of communication and marketing. He joins the company from AAB Consulting, where he worked with Sobi Pharmaceuticals on enhancing commercial capabilities for rare disease. Prior to that, he led marketing communication and excellence at Smith & Nephew, and before that, he held several positions at Astra Zeneca. Baxevanis has an MBA from the Alba Graduate Business School and a master's degree in chemical engineering from the University of Patras in Greece.

May 05, 2020

Grail: Mostafa Ronaghi

Mostafa Ronaghi has joined Grail's board of directors. Ronaghi is currently Illumina's senior vice president of entrepreneurial development, and previously served as the company's senior VP and chief technology officer, a role in which he led internal research and technology and cofounded Grail. He also cofounded the Illumina Accelerator.

In 2007, Ronaghi cofounded Avantome, a privately held sequencing company that was acquired by Illumina in 2008. Before this, he cofounded NextBio, a search engine for life science data that was acquired by Illumina in 2013. In 2001, Ronaghi cofounded ParAllele Bioscience, which was eventually acquired by Affymetrix, and was involved in the development and commercialization of highly multiplexed technology for genetic testing. In 1997 he cofounded Pyrosequencing AB, which was renamed Biotage in 2003. Ronaghi earned his PhD from the Royal Institute of Technology in Sweden and was a principal investigator at Stanford University from 2002 until 2008, focused on the development of novel tools for molecular diagnostic applications. He also serves on the board of directors of BaseHealth and Clear Labs. 

May 05, 2020

RevoluGen: John Chisholm

RevoluGen has appointed John Chisholm as non-executive chairman. Chisholm was most recently executive chairman of Genomics England where he oversaw the 100,000 Genome Project. RevoluGen said that Chisholm will lend his expertise to the development of the company's business including optimizing applications for its Fire Monkey/Fire Flower high-molecular-weight DNA sample prep products.

May 04, 2020

Illumina: Alex Aravanis, Mostafa Ronaghi

Illumina announced that Alex Aravanis will join the company in June as Chief Technology Officer. He will be responsible for leading the firm's R&D functions as well as translation of next-generation sequencing into the clinic. He will report to CEO Francis deSouza.

Aravanis returns to Illumina from Grail, where he was chief scientific officer and head of R&D; he was also a cofounder. At Grail, he led development of that firm's multi-cancer early detection test. While at Illumina, he developed clinical assays and bioinformatic pipelines for the analysis of RNA and DNA from fixed tissues, whole-exome analysis, massively parallel single-cell transcriptomics, and liquid biopsy using cell-free nucleic acids. He holds both an MD and a doctorate in electrical engineering from Stanford University.

Aravanis will replace current CTO Mostafa Ronaghi, whom Illumina has appointed to lead global entrepreneurial development. Ronaghi is also a Grail cofounder and launched the Illumina Accelerator program in 2014, and was recently appointed to Grail's board of directors.

May 04, 2020

Bionano Genomics: Hannah Mamuszka, Yvonne Linney, Junfeng Wang

Bionano Genomics has added Hannah Mamuszka and Yvonne Linney to its board of directors. Junfeng Wang, who joined the board as a representative of Legend Capital, has resigned from the board.

Mamuszka is the founder and CEO of Alva 10, an advisor on reimbursement for diagnostic testing. Prior to that, she was VP of Business Development and Clinical Strategy at Exosome Diagnostics. She has also held leadership positions at Asuragen, Oncotech, and Millennium Pharmaceuticals. She holds a master's degree in molecular biology from Harvard University.

Yvonne Linney is the founder of Linney BioConsulting. She has also served as CEO of Transcriptic, now operating as Strateos, where she was also COO and served on the board, and served in executive positions at Agilent Technologies, Bayer Diagnostics, and Caliper Life Sciences. She holds a doctorate in genetics from Leicester University in the UK.

Apr 30, 2020

Cleveland Clinic: Timothy Chan

Timothy Chan has been appointed director of the Center for Immunotherapy and Precision Immuno-oncology at Cleveland Clinic. Chan joins the clinic from Memorial Sloan Kettering Cancer Center and Weill Cornell School of Medicine, where he chaired the immunogenomics and precision oncology platform and was a tenured professor. He also was chair of the translational oncology division. Chan also joins the leadership of the National Center for Regenerative Medicine of Case Western Reserve University; and is on staff at the Genomic Medicine Institute of the Lerner Research Institute and the Department of Radiation Oncology of the Taussig Cancer Institute. He holds an MD and PhD in genetics from Johns Hopkins University, where he also completed a residency in radiation oncology and postdoc in tumor biology.

Apr 29, 2020

Transplant Genomics: Peter Meintjes

Eurofins-Transplant Genomics has appointed Peter Meintjes as chief commercial officer to lead the commercialization of the company's TruGraf blood test for kidney transplant surveillance. Meintjes joins TGI after six years at Omixon, where most recently served as CEO after having also held the roles of chief commercial officer and director of US operations. Meintjes also previously worked as VP of business development for Biomatters.

Apr 29, 2020

Grail: Satnam Alag

Grail has appointed Satnam Alag as senior VP of software engineering. Prior to Grail, Alag most recently served as VP of software engineering, product development at Illumina. Before Illumina, Alag was chief technology officer at NextBio, which was acquired by Illumina in 2013. Alag has also held other senior software architecture positions, including chief software architect at Deem.  

Apr 24, 2020

HTG Molecular Diagnostics: Maureen Cronin

Maureen Cronin has resigned as CSO and senior VP at HTG Molecular Diagnostics, effective April 30. She will resume her consulting practice to pursue other interests, the company said. Cronin joined HTG Molecular in November 2018 after serving as executive director of strategic information management for Celgene from 2012 to 2017. Before that, she was senior VP of research and product development for Foundation Medicine. She also served as VP of translational research and senior director of technology development at Genomic Health.

Pages

A tissue sample from the 1960s harbors a near-complete sample of HIV, IFLScience reports.

A new bill would reshape the US National Science Foundation to include a focus on technological development, according to Science.

The Food and Drug Administration's decision to halt a SARS-CoV-2 study has drawn criticism, according to Stat News.

In Genome Biology this week: features affecting gut microbiome and parasite patterns, cellular interactions in lung tumor microenvironment, and more.